ArticleAnnals of burns and fire disasters2015
[Not Available].
Article in Annals of burns and fire disasters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- [The ambient air andAnnals of burns and fire disasters · 2024Article
- Article
- Article
- Article
- Article
- Article
- Article
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mortality in burn patients is most often caused by infections, which are frequently bacterial. These patients are subject to loss of the cutaneous barrier, invasive devices and immunosuppression which are all contributing factors to the onset of infections. Unfortunately, it is not easy to distinguish general signs of infection from other symptoms associated with burn injuries, making diagnosis difficult. Since infection is a great threat in burns patients, its prevention is a fundamental part of the treatment process. Moreover, due to the anomalous pharmacokinetic characteristics of burns patients, it is also mandatory to adapt any antimicrobial regimen to the outcomes of regular patient blood tests and sampling. At a time when bacterial resistance is becoming an increasing concern, research on alternative treatment (e.g. inhibitors of virulence factors, antimicrobial peptides, polyphenols, immunotherap, and so on) is crucial. One of the more promising possibilities in this area seems to be phagotherapy.
Identifiers
27252607PMC4837499W4292679827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.